

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR Maria K. Boden Wastfelt 012889-086 3731 09/938,497 08/27/2001 **EXAMINER** 21839 05/12/2004 BURNS DOANE SWECKER & MATHIS L L P LANDSMAN, ROBERT S POST OFFICE BOX 1404 ART UNIT PAPER NUMBER ALEXANDRIA, VA 22313-1404 1647

DATE MAILED: 05/12/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No.	Applicant(s)
	09/938,497	BODEN WASTFELT ET AL.
	Examiner	Art Unit
	Robert Landsman	1647
The MAILING DATE of this communication appears on the cover sheet with the correspondence address		
THE REPLY FILED 28 April 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.		
PERIOD FOR REPLY [check either a) or b)]		
a) The period for reply expires 3_months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.		
2. The proposed amendment(s) will not be entered because:		
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);		
(b) ☐ they raise the issue of new matter (see Note below);		
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or		
(d) they present additional claims without canceling a corresponding number of finally rejected claims.		
NOTE:		
3. Applicant's reply has overcome the following rejection(s): See Continuation Sheet.		
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).		
5.⊠ The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.		
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.		
7.⊠ For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>12,13,18 and 19</u> .		
Claim(s) withdrawn from consideration:		
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.		
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)		
10. Other:		

Continuation of 3. Applicant's reply has overcome the following rejection(s): the objection to the specification regarding the omitted sequence identifiers. The rejection of claim 19 under 35 USC 112, first paragraph - both enablement and written description, regarding "pharmaceutically acceptable carrier" has been withdrawn.

Continuation of 5. does NOT place the application in condition for allowance because: the claims remain objected to regarding the phras "derived from." Claims 12, 13, 18 and 19 remain rejected under 35 USC 102 for the reasons already of record on page 5 of the Office Action dated 1/28/04. Applicants will receive the PCT date of 9/20/93. It is not clear if foreign priority has been perfected, nor have english translations of the foreign documents been provided. However, Boden is still 102(b) art. Applicants' argument that Boden did not teach the fragments of the protein of the present invention is not persuasive as this is an inherent property of the protein. Since the Office does not have the facilities for examining and comparing applicants' protein with the protein of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the protein of the prior art does not possess the same material structural and functional characteristics of the claimed protein). See In re Best, 562 F.2d 1252, 195 USPQ 43 (CCPA 1977) and Ex parte Gray, 10 USPQ 2d 1922 1923 (PTO Bd. Pat. App. & Int.).

ROBERT LANDSMAN PATENT EXAMINER